BioNexus Gene Lab Director Yap Chee Keong Receives Stock Award

What Happened Yap Chee Keong, a director of BioNexus Gene Lab Corp. (BGLC), was granted a fully vested other stock‑based award of 32,258 shares of common stock on August 13, 2026. The Form 4 lists the transaction price as N/A, but the award was valued for plan purposes at $1.55 per share (Nasdaq close on Aug 12, 2026), giving an aggregate plan value of $49,999.90. The award was granted under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan for completed services and required no cash payment.

Key Details

• Transaction date: August 13, 2026; Form 4 filed August 14, 2026 (timely filing).
• Transaction type/code: Award/Grant (A) — fully vested other stock‑based award.
• Shares granted: 32,258; Plan valuation: $1.55 per share; total plan value ≈ $49,999.90.
• Consideration: No cash consideration; award granted for completed services under the 2025 Equity Incentive Plan (see footnote F1).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: F1 confirms fully vested status, plan valuation method (Nasdaq close 8/12/2026), and that award was granted for services.

Context This was a compensatory equity award to a director, not an open‑market purchase or sale. Because the award is fully vested, Yap now beneficially owns the shares (unless restricted by other company rules), but there is no immediate sale reported. Such awards are common for director compensation and do not by themselves indicate a buy or sell signal.